Relmada’s Phase III Depression Study Scuppered By ‘Placebo Paradox’
Adjunctive Studies Will Continue
Executive Summary
An unexpectedly strong response in the placebo arm has derailed a monotherapy study of Relmada’s investigational antidepressant REL-1017, but the company will continue its trials as an adjunctive therapy.